# SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct07254585/  
OnCo record `nct07254585` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SYS6010 in head and neck squamous cell carcinoma, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.

## Summary

SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT07254585 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 70 participants planned, started 2025-12-18 and due to reach its primary completion in 2026-06-30. Interventions recorded: SYS6010 injection, Enlonstobart injection. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07254585
- Phase: 2
- Setting: An Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of SYS6010 Combined With Enlonstobart in the Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT07254585: https://clinicaltrials.gov/study/NCT07254585

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [SYS6010](https://onco.cc/drugs/sys6010/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct07254585.json